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ABSTRACT
Background Subthalamic nucleus (STN) deep brain
stimulation (DBS) represents a well-established treatment
for patients with advanced Parkinson’s disease (PD)
insufﬁciently controlled with medical therapies. This study
presents the long-term outcomes of patients with PD
treated with STN-DBS using an MRI-guided/MRI-veriﬁed
approach without microelectrode recording.
Methods A cohort of 41 patients who underwent STN-
DBS were followed for a minimum period of 5 years, with a
subgroup of 12 patients being followed for 8–11 years.
Motor status was evaluated using part III of the Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS-III), in on- and
off-medication/on-stimulation conditions. Preoperative and
postoperative assessments further included activities of
daily living (UPDRS-II), motor complications (UPDRS-IV),
neuropsychological and speech assessments, as well as
evaluation of quality of life. Active contacts localisation was
calculated and compared with clinical outcomes.
Results STN-DBS signiﬁcantly improved the off-
medication UPDRS-III scores, compared with baseline.
However, UPDRS scores increased over time after DBS.
Dyskinesias, motor ﬂuctuations and demands in
dopaminergic medication remained signiﬁcantly reduced in
the long term. Conversely, UPDRS-III on-medication scores
deteriorated at 5 and 8 years, mostly driven by axial and
bradykinesia subscores. Quality of life, as well as
depression and anxiety scores, did not signiﬁcantly change
at long-term follow-up compared with baseline. In our
series, severe cognitive decline was observed in 17.1% and
16.7% of the patients at 5 and 8 years respectively.
Conclusions Our data conﬁrm that STN-DBS, using an
MRI-guided/MRI-veriﬁed technique, remains an effective
treatment for motor ‘off’ symptoms of PD in the long term
with low morbidity.
INTRODUCTION
High-frequency deep brain stimulation (DBS) of the
subthalamic nucleus (STN) is a well-established surgi-
cal treatment for symptoms of Parkinson’s disease
(PD) insufﬁciently controlled with medical therapies.
In 2005, STN DBS was granted the label of efﬁca-
cious symptomatic treatment at the Movement
Disorder Society (MDS) evidence-based medicine
review update of treatments for PD.1 The European
Federation of Neurological Societies (EFNS) and
MDS—European Section recent collaboration to
produce evidence-based recommendations for the
treatment of PD accredited DBS with level A evidence
for the management of disabling tremor, severe
motor complications, unpredictable on–off periods,
dyskinesias (including biphasic dyskinesias), off-
periods and early-morning dystonia.2 STN DBS has
been used for the treatment of patients with PD since
the mid-1990s.3 4 Short-term and medium-term out-
comes are well documented by several studies,
showing substantial improvements in motor symp-
toms and quality of life, and reduction in dopamin-
ergic medication requirements.5–8 Far fewer studies
have reported on the effects of microelectrode-guided
STN DBS after prolonged follow-up periods.9–11
According to a recent review including STN DBS
studies with long-term follow-up data, substantial
beneﬁts for some of the motor symptoms, namely,
tremor, rigidity, as well as motor complications, were
maintained after 5 years.12 However, the same studies
noted that akinesia, axial signs and cognition often
deteriorated in the long term, most likely in keeping
with the natural progression of the disease and the
involvement of non-dopaminergic systems.
The major risks associated with the surgical pro-
cedure include intracranial bleeding and infection of
the implanted material. Microelectrode recording
(MER) identiﬁes the neuronal ﬁring patterns of the
STN and currently represents the most commonly
employed technique to assist and validate target
localisation.6 Our group has previously published
12-month safety and efﬁcacy data on a large series
of patients with PD (n=79) treated with STN DBS
using a standardised surgical technique based on
individual MRI-guided and MRI-veriﬁed targeting
without MER. This approach reduces the number of
brain penetrations required and the associated risk
of morbidity.13 14 Here, we report the long-term
outcome in a cohort of individuals who underwent
STN DBS at our institution (n=41) and were fol-
lowed for a minimum period of 5 years, with a sub-
group of patients (n=12) being followed for 8–
11 years. To our knowledge, this is the ﬁrst study
presenting long-term outcomes of patients treated
with high-frequency STN DBS using MRI-guided
and MRI-veriﬁed approach without MER.
METHODS
Study design
Clinical assessments were done in a non-blinded
fashion. All data were prospectively collected and
retrospectively analysed.
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Patients
Forty-ﬁve consecutive patients with PD were implanted with
bilateral STN DBS electrodes between November 2002 and
September 2006 at the National Hospital for Neurology and
Neurosurgery. Forty-one patients were followed for at least
5 years and were thus included in the present study. For a subset
of 12 of these patients, follow-up data beyond 7 years were
available. The remaining four of the initial cohort could not
complete 5-year follow-up visits due to death (n=3) or being
bed bound following stroke 3 years after surgery (n=1), in all
cases unrelated to DBS surgery, and were therefore not included
in the present study.
Each patient underwent a multidisciplinary evaluation to
decide on the suitability of STN DBS surgery. All patients had a
diagnosis of idiopathic PD according to the UK Brain Bank cri-
teria, for at least 5 years, age younger than 70 years, and suf-
fered from disabling motor complications despite optimal
medical treatment. A formal levodopa challenge conﬁrmed
dopaminergic drug responsiveness. Detailed neuropsychological
and neuropsychiatric assessments excluded patients with signiﬁ-
cant cognitive impairment and/or ongoing psychiatric comorbid-
ities. A structural MRI was obtained to exclude surgical
contraindications. Written informed consent was obtained from
each patient before surgery. Table 1 summarises the character-
istics of patients at baseline.
Surgical procedure and stimulation programming
Details of our neurosurgical procedure, using an MRI-guided
and MRI-veriﬁed technique, have been previously described.13 15
Brieﬂy, implantation of bilateral quadripolar DBS electrodes
(3389 Medtronic, Minneapolis, MN) was performed under
local anaesthesia, in the off-medication condition (see below) to
allow clinical evaluations during electrode placement.
Monopolar stimulation through the contacts of the DBS elec-
trode was sequentially performed to assess for additional thera-
peutic effects and/or the presence of side effects. One patient
did not tolerate the off-medication condition, and surgery was
performed under general anaesthesia. The STN was visualised
on stereotactic T2-weighted MRI sequences and directly tar-
geted using manual calculation and/or planning software
(FrameLink, Medtronic, Minneapolis, Minnesota, USA),
without MER. An immediate postoperative stereotactic MRI
was performed to verify accurate electrode placement. The
pulse generator(s) (Soletra or Kinetra, Medtronic, Minneapolis,
Minnesota, USA) was implanted in the subclavicular area and
connected subcutaneously to the electrodes under general anaes-
thesia either immediately or a few days after electrode
implantation.
Stimulation was initiated within the ﬁrst postoperative week,
and optimal settings were selected through a screening process.
Stimulation and medication were further titrated according to
clinical response over subsequent visits.
Clinical assessments
All 41 patients were assessed preoperatively and postoperatively
at 1 year (mean±SD 1.1±0.3 years; range 0.8–2 years) and at
5 years (mean±SD 5.2±0.5; range 4.5–6 years). Twelve patients
were further assessed at 8 years (mean±SD 8.1±1.6; range 7.2–
11 years). Each visit included motor, neuropsychological and
speech assessments, as well as evaluation of quality of life,
which were carried out the same day or within two consecutive
days for each patient.
Motor status was evaluated using part III of the Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS-III). Prior to surgery,
patients were assessed in the practically deﬁned ‘off state’ after
overnight withdrawal of antiparkinsonian drugs, and the ‘on
state’, following a levodopa challenge using a suprathreshold
dose of oral levodopa. After bilateral STN DBS, motor assess-
ments were sequentially performed at the following conditions,
in open fashion: off medication/on stimulation (with stimulation
switched on after 12 h medication withdrawal); on medication/
on stimulation (1 h after the administration of a suprathreshold
dose of levodopa while stimulation was reintroduced).
Subscores for individual cardinal features of PD were derived by
summation of the relevant items from the UPDRS-III as follows:
tremor (items 20–21), rigidity (item 22), bradykinesia (items
23–26, 31) and axial (18, 19, 27–30).
Evaluations also included the UPDRS parts II (activities of
daily living (ADL)) and IV (motor complications). UPDRS-IV
was divided further into two subscores; items 32–34 to assess
dyskinesias and items 35–39 to reﬂect motor ﬂuctuations (on–
off phenomena).
Quality of life was assessed with the Parkinson’s Disease
Questionnaire 39 (PDQ-39). The 39 items encompass the fol-
lowing domains: mobility, ADL, emotional health, stigma, social
support, cognition, communication and bodily discomfort.
A summary score from 0 to 100 was calculated for the PDQ-39.
This summary index (SI) is the arithmetic mean of the scores
for the individual domains.16
Global cognitive functions were tested with the Mattis
Dementia Rating Scale (DRS-2). Further analyses were done on
the scale components (attention, initiation/perseveration, con-
struction, conceptualisation and memory). The Age-Corrected
Mayo’s Older Americans Normative Studies (MOANS) Scaled
Score (AMSS) was computed from raw total and subscores.17
The test was performed at best clinical condition, under regular
medication at baseline, and under current medication and
on-stimulation at postoperative follow-ups.
The presence of dementia was clinically deﬁned according to
the criteria in the Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV).
The Beck Depression Inventory (BDI) and the Beck Anxiety
Inventory (BAI) were used to evaluate mood.
Speech was assessed by a speech therapist using the sentence
task of the Assessment of Intelligibility for Dysarthric Speech
(AIDS); this is the percentage of words correctly understood by
a native English speaker blinded to patient status.18
Each patient’s medication dose was recorded at each time
point, and levodopa equivalent dose (LED) was derived using a
standard formula.19
Stimulation settings were documented and the average
voltage, pulse width and frequency were calculated for all active
contacts for each patient.
Adverse events were systematically documented.
Table 1 Characteristics of patients at baseline
5-year follow-up
(n=41)
8-year follow-up*
(n=12)
Gender distribution 27 men, 14 women 8 men, 4 women
Age at onset (mean±SD, years) 43.3±9.8 40.4±9.8
Age at surgery (mean±SD, years) 56.2±8.4 52.8±10.1
Disease duration (mean±SD years) 12.9±5.8 12.3±4
L-dopa equivalent dose (LED) 1471±515 1475±525
*Baseline features between the total cohort and the patients followed beyond 8 years
did not differ significantly.
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Active contact localisation
Preoperative stereotactic T2-weighted scans were used to visual-
ise the MRI-deﬁned STN in both the axial and the coronal
planes. The STN was subdivided into ﬁve segments: superior
(A), anterior-medial (B), central (C), posterolateral (D) and
inferior (E). The stereotactic coordinates of each active contact
were calculated from postoperative stereotactic MR images and
transposed to the preoperative scan. A functional neurosurgeon,
blinded to the clinical outcome, then determined which STN
segment the active contact was most closely related to, as previ-
ously described.18 The position of each active contact was
further classiﬁed according to the established functional subsec-
tions of the STN.20 21 Consequently, contacts associated with
A or D segments were considered as stimulating the sensori-
motor area of the STN, segment C the associative and in B or E
the limbic area of the STN.
Statistical analysis
Clinical outcomes for continuous values are presented as mean
±SD. All numeric values were checked for normality using
One-Sample Kolmogorov–Smirnov analysis. Continuous data
comparing baseline and postoperative scores were analysed by
means of the Student t test, if normally distributed.
Alternatively, the Wilcoxon signed-rank test was used for non-
parametric data. Differences between independent groups were
tested with one-way analysis of variance or the Kruskal–Wallis
test, according to data distribution.
Correlations of clinical parameters with motor response to
DBS and changes in global cognitive function at 5 and 8 years
postoperatively were assessed by Spearman correlation coefﬁ-
cients. Linear regression analysis, as guided by univariate ana-
lysis outcome, was used to explore the impact of baseline
factors to the abovementioned changes.
The motor response to DBS was calculated as follows: (base-
line off-medication score minus postoperative off-medication
on-stimulation score)/baseline off-medication score)×100 (posi-
tive scores denote improvement).
Change in global cognitive function was calculated as follows:
(baseline DSR-2 AMSS minus postoperative DRS-2 AMSS)/base-
line DSR-2 AMSS×100 (positive scores denote deterioration).
To allow clinically meaningful comparisons between clinical
outcomes controlled by continuous bilateral stimulation, a com-
bined contact score, taking into account both left and right elec-
trodes, was adopted for each patient as follows: (1) both active
contacts assigned to the sensorimotor area or one contact
assigned to the sensorimotor area and one to the associative; (2)
both active contacts assigned to the associative or one to the
sensorimotor area and one to the limbic area and (3) both in
the limbic area or one in the associative and one in the limbic
area of the STN.
All reported p values are two-sided at a signiﬁcance level of
0.05. All data were analysed using the SPSS statistical package
(SPSS, Release V.21.0 Chicago, Illinois, USA).
RESULTS
Motor outcomes
Off medication
STN DBS signiﬁcantly improved the UPDRS-III score with
respect to baseline at all follow-up points. However, an increase
in UPDRS scores was observed over time on DBS (table 2, see
online supplementary ﬁgure). Analysis of UPDRS-III subitems
showed that STN DBS provided signiﬁcant and persistent relief
from tremor (72.6% reduction at 1 year, 73.9% at 5 years and
77.2% at 8 years) and rigidity (53.9% reduction at 1 year,
45.2% at 5 years and 50% at 8 years). Signiﬁcant, but less
remarkable, improvements were seen in bradykinesia (45.8%
reduction at 1 year, 16.5% at 5 years and 23.2% at 8 years) and
axial symptoms by 53.6% at 1 year, 41.2% at 5 years and
21.6% at 8 years. Speech intelligibility signiﬁcantly deteriorated
at 5 (−43.7%) and 8 years (−21.4%).
On medication
UPDRS-III scores during the on-medication–on-stimulation con-
dition did not change signiﬁcantly at 1 year postoperatively in
comparison to baseline. However, deterioration was observed
after 5 and 8 years; this was signiﬁcant at 5 years, but in the
smaller sample did not reach signiﬁcance at 8 years (table 3).
Rigidity subscore was signiﬁcantly improved at 1 year
(28.6%). Tremor and rigidity were improved at 5 years,
although this was not signiﬁcant. On the other hand, both bra-
dykinesia and axial subscores deteriorated signiﬁcantly at 5 and
8 years. Speech intelligibility declined signiﬁcantly at 5
(−48.5%) and 8 years (−39.6%).
ADL
ADL in the off-medication state (UPDRS-II) improved with DBS
at 1, 5 and 8 years. However, ADL scores in the on-medication
state did not improve after STN stimulation (tables 2 and 3).
Table 2 Effects of STN DBS during the off-medication condition
Mean±SD scores*
(possible range)
Baseline
(n=41)
Baseline of
8-year
follow-up
(n=12)
1 year
post-op
5 years
post-op
8 years
post-op
p Value
(1 year vs baseline)
p Value
(5 years vs baseline)
p Value
(8 years vs baseline)
Total UPDRS-III
(0–108)
50.3±15.8 57±15.2 22.9±12.8 33.7±8.7 36.2±16.9 <0.001 <0.001 <0.001
Tremor (0–28) 7.3±4.1 7.9±3.6 2±2.6 1.9±1.6 1.8±1.8 <0.001 <0.001 <0.001
Rigidity (0–20) 11.5±4.4 13±4.1 5.3±3.6 6.3±2.9 6.5±5 <0.001 <0.001 <0.001
Bradykinesia (0–36) 21.8±7.1 25±6.5 11.8±7.1 18.3±5 19.2±8.4 <0.001 0.03 0.019
Axial (0–24) 9.7±4.6 11.1±5.4 4.5±3.5 7.7±3.1 8.7±4.7 <0.001 0.027 0.03
UPDRS-II (ADL) (0–52) 23.3±7.4 29.4±6.8 15.6±8.4 20.7±7 21±7.5 <0.001 0.194 0.043
On–off fluctuation (0–7) 4.7±1.4 5.6±1.2 2.3±1.8 2.5±1.8 2.8±1.8 <0.001 <0.001 0.006
Speech intelligibility (0–100) 91.9±11.8 80.8±18.7 70.2±7.2 51.7±4.6 63.5±2.1 >0.05 <0.001 <0.001
*For all outcome measures, higher scores indicate worse condition but for speech intelligibility, where higher scores are indicative of better performance.
ADL, activities of daily living; DBS, deep brain stimulation; STN, subthalamic nucleus; UPDRS, Unified Parkinson’s Disease Rating Scale.
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PDQ-39
PDQ-39 SI (score) improved by 26.1% at 1 year (p=0.008), but
had almost returned to baseline 5 and 8 years post-DBS
(table 4). Improvement in four of the eight PDQ-39 subdomains
persisted up to 8 years following surgery: mobility, ADL, stigma
and bodily discomfort. However, the support subdomain
remained generally unchanged over time. Comparison analyses
showed an improvement in bodily discomfort subdomain; but
only at 5-year follow-up there was a statistically signiﬁcant dif-
ference (p=0.013). Conversely, emotional well-being and cogni-
tion subdomains tended to decline at 5 and 8 years compared
with baseline, although this was not signiﬁcant. Communication
was the only subdomain that deteriorated signiﬁcantly at 5
(p=0.002) and 8 years (p=0.002) in comparison to preopera-
tive mean scores.
Drug-related motor complications
Signiﬁcant improvements in drug-related motor complications
were sustained over time as measured by the subitems of
UPDRS-IV. Dyskinesias ameliorated by 50.0% at 1 year, 61.4%
at 5 years and 52.3% at 8 years (table 2). On–off motor ﬂuctua-
tions reduced by 51.1% at 1 year, 46.8% at 5 years and 50.0%
at 8 years after surgery (table 2).
Neuropsychological evaluations
Results of neuropsychological evaluations are shown in table 5.
DRS-2 AMSS scores were stable at 1 year postoperatively, but
tended to decline at 5 and 8 years. Nevertheless, p values at
8 years did not reach the chosen level of signiﬁcance for either
total scores or the separate cognitive subdomains. Attention and
conceptualisation subscores did not signiﬁcantly change at
5 years, while initiation/perseveration, construction and memory
got signiﬁcantly worse (table 5).
Dementia as deﬁned by DSM-IV criteria was present in one
patient (2.4%) at 1-year post-DBS, seven patients at 5 years
(17.1%) and two patients (16.7%) among the ones followed by
8 years. There were no signiﬁcant changes in BDI and BAI at 5
and 8 years.
Medical treatment, stimulation parameters and device
replacements
The mean preoperative LED decreased by 35.4% at 1 year
(from 1471.1±515.2 to 949.6±572.7, p<0.001), 45.1% (from
1471.1±515.2 to 668.5±359.3, p<0.001) at 5 years and
48.6% (from 1475±525 to 698.8±541.8, p=0.009) at 8 years.
One patient was completely drug-free 1 year after surgery, and
remained drug-free after 5 and 8 years.
There were no signiﬁcant changes in the stimulation ampli-
tude (voltage) from 1 year (3.1±0.7 V) to 5 (3.2±0.7 V) or
8 years (3.11±0.9). Pulse width did not vary signiﬁcantly over
time (1 year 60.4±2.4 ms; 5 years 63.8±12.5 ms and 8 years
61.5±5 ms). The mean stimulation frequency increased slightly
but not to a signiﬁcant degree (1 year 139.5±18.9 Hz; 5 years
142.7±24.1 Hz and 8 years 149.5±14.1 Hz). Bilateral
Table 3 Effects of STN DBS during the on-medication condition
Mean±SD scores*
(possible range)
Baseline
(n=41)
Baseline of
8- year follow-up
(n=12)
1 year
post-op
5 years
post-op
8 years
post-op
p Value
(1 year vs baseline)
p Value
(5 years vs baseline)
p Value
(8 years vs baseline)
Total UPDRS-III (0–108) 14±8.7 16.5±9.8 14±10 23.9±10.1 28.7±16.1 0.805 <0.001 0.063
Tremor (0–28) 1.4±2.3 1.5±1.7 0.8±1.3 0.91±1.1 1.5±1.1 0.184 0.37 0.664
Rigidity (0–20) 4.2±3.1 4.5±3.4 3±3.1 3.4±2.7 5.8±5.1 0.038 0.388 0.600
Bradykinesia (0–36) 6.3±4.2 7.7±5 7.4±5.2 12.7±5.6 14.7±7 0.335 <0.001 0.025
Axial (0–24) 2.5±2.1 3±2.1 2.9±2.4 6.1±3.5 6.6±3.8 0.475 <0.001 0.006
UPDRS-II (ADL) (0–52) 6.2±5 8.18±4.3 7.5±4.8 13.2±7.5 15.2±8.1 0.251 <0.001 0.011
Dyskinesias (0–13) 3.6±2.5 4.4±2.5 1.8±2.2 1.39±1.8 2.1±2.1 0.007 0.002 0.053
Speech intelligibility
(0–100)
89±3.6 80.8±18.7 67.5±6.8 45.8±11 40.8±19.1 <0.05 <0.001 <0.001
*For all outcome measures, higher scores indicate worse condition but for speech intelligibility, where higher scores are indicative of better performance.
ADL, activities of daily living; DBS, deep brain stimulation; STN, subthalamic nucleus; UPDRS, Unified Parkinson’s Disease Rating Scale.
Table 4 STN-DBS effects on PDQ-39 summary index (SI) and different subdomains
Mean scores±SD
(possible range)
Baseline
(n=41)
Baseline of
8-year
follow-up
1 years
post-op
5 years
post-op
8 years
post-op
p Value
(5 years vs baseline)
p Value
(8 years vs baseline)
PDQ-39 SI (0–100)* 38.2±17.2 45.6±19.2 28.9±14.2 37.5±18.5 44.9±15.1 0.886 0.932
Mobility 50.9±24.9 55.9±29.8 35.8±27.6 42.4±29.0 51.8±28.9 0.414 0.713
Activities daily living 39.6±18.8 49.6±20.4 23.0±14.7 36.3±22.7 39.0±17.0 0.759 0.131
Emotional 21.8±14.9 23.1±15.6 18.0±18.2 22.3±20.2 23.9±16.0 0.961 0.866
Stigma 24.1±21.8 31.8±23.5 17.9±16.9 16.3±16.6 22.2±19.9 0.162 0.364
Support 12.7±13.7 15.9±12.0 8.0±11.0 14.5±19.7 14.4±21.8 0.711 0.837
Cognition 21.9±14.8 23.3±17.0 20.4±13.4 28.0±15.8 24.4±12.3 0.709 0.870
Communication 27.7±24.2 33.3±28.6 31.1±21.7 40.8±22.6 61.4±22.8 0.002 0.002
Bodily discomfort 46.2±26.2 54.6±27.7 28.3±20.8 33.0±21.9 47.7±21.8 0.013 0.520
*Higher scores indicate worse condition.
DBS, deep brain stimulation; STN, subthalamic nucleus.
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monopolar stimulation was applied in 35 patients (85.4%). Four
patients received unilateral double monopolar stimulation
(9.7%) and two received bilateral double monopolar stimulation
in the 5-year follow-up (4.9%), and one (8.3%) had unilateral
double monopolar stimulation in the 8-year follow-up group,
and the remaining patients were on bilateral monopolar
stimulation.
No implantable pulse generator (IPG) replacement occurred
among the patients followed at 5 years. Out of the 12 patients
followed in the 8-year group (range 7.2–11 years), two had two
IPG replacements and seven had one, under general anaesthesia
without complications. The remaining three had no IPG repla-
cements. Bilateral new Soletra IPGs were replaced in one patient
and Kinetra IPG in the others, after a mean period of 5.9
±1 years.
Active contacts position
At 5 years, 44.1%, 35.3% and 20.6% of active contacts were
most closely associated with the motor, associative and limbic
regions of the STN, respectively. In the subgroup of patients
with 8-year follow–up, 62.5% of active contacts were associated
with the motor and 37.5% the associative regions of the STN.
Correlations of clinical outcomes
The magnitude of the motor response to DBS correlated posi-
tively with younger age at disease onset (p=0.02). Younger age
at surgery demonstrated a non-signiﬁcant trend towards better
motor response to DBS (p=0.07). Worse UPDRS-III off scores
at baseline (both total and subscores) and more severe on–off
ﬂuctuations also correlated with signiﬁcantly better post-
operative motor responses. Younger age at surgery and better
preoperative levodopa responsiveness, as measured by levodopa
challenge, showed a positive trend towards a better motor
response to DBS (p=0.07 and 0.064). After multivariate regres-
sion analysis, only higher tremor subscores in the off condition
were found to be an independent factor of better clinical
outcome (p=0.001).
Deterioration in DRS-2 scores was associated with older age
at baseline, worse motor state in the on condition (UPDRS-III
on), worse quality of life at baseline and higher medication
requirements as measured by LED. None of the abovemen-
tioned factors reached a level of statistical signiﬁcance when
checked in the multivariate analysis.
A better motor outcome was documented when contacts’
location calculated score was 1 (= both active contacts assigned
to the sensorimotor area of the STN or one contact assigned to
the sensorimotor area and one to the associative) in comparison
to 2 (= both active contacts assigned to the associative area of
the STN or one to the sensorimotor area and one to the limbic
area) and 3 (= both in the limbic area or one in the associative
and one in the limbic area of the STN). Signiﬁcantly worse
motor outcomes at 5 years were correlated with contact calcu-
lated score 3 in comparison to 1 (p=0.046) (ﬁgure 1).
Adverse effects
All patients underwent stereotactic MRI immediately after lead
implantation. There were no haemorrhages (either symptomatic
or asymptomatic). In this group of patients, there were no hard-
ware infections in the primary procedure or at impulse gener-
ator replacement. There were no DBS malfunctions, lead
fractures or lead migrations. Two patients had their electrodes
repositioned due to insufﬁcient response from the ﬁrst
operation.
Table 5 Neuropsychological evaluations
Mean scores±SD
(possible range)
Baseline
(n=41)
Baseline of
8-year follow-up
1 year
post-op
5 years
post-op
8 years
post-op
p Value
(5 years vs baseline)
p Value
(8 years vs baseline)
Total DRS-2 raw (0–144)* 141.3±.2.2 141.6±2.7 140.8±5.3 134.4±13.4 137.8±5.5 0.01 0.087
Total DRS-2 AMSS 12.4±1.9 12.9±2.2 12.7±3 9.9±3.7 11.2±3.4 0.001 0.404
Attention 11.8±1.3 12.1±1.0 11.9±1.6 11.8±2 11.2±2.0 0.937 0.477
Initiation/perseveration 10.3±1.4 9.7±2.3 10.2±2.6 8.2±3.2 8.9±3.0 0.001 0.374
Construction 10±0 10.0±0.0 9.6±1.4 9±2.3 9.6±1.1 0.03 0.374
Conceptualisation 11.1±1.4 12.0±0.0 11.6±1.1 10.2±2.5 11.6±0.9 0.180 0.374
Memory 11.9±1.8 11.6±1.9 11.8±2.7 9.1±3.6 10.4±2.5 0.002 0.690
BDI (0–63)† 10±5.4 14.0±7.1 8.3±4.2 11±6.3 11.1±3.2 0.084 0.531
BAI (0–63)† 14.5±8.6 20.0±9.2 10.3±7.3 12.4±8.4 16.1±7.0 0.458 0.313
*Higher scores indicate better cognitive performance.
†Higher scores indicate more severe symptoms of depression and anxiety.
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory.
Figure 1 Percentage of changes in the Uniﬁed Parkinson’s disease
Rating Scale (UPDRS-III) following subthalamic nucleus (STN) deep
brain stimulation (DBS) at 5 years in relation to active contact location
calculated score (1=both active contacts assigned to the sensorimotor
area of the STN or one contact assigned to the sensorimotor area and
one to the associative; 2=both active contacts assigned to the
associative area of the STN or one to the sensorimotor area and one to
the limbic area; 3=both in the limbic area or one in the associative and
one in the limbic area of the STN).
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Five patients had a transient delirium/confusion episode
during the ﬁrst days after surgery. One patient suffered seizures
during the 48 h after surgery but did not develop epilepsy.
There was no severe depression, suicide or attempted suicide.
There were four cases of impulse control disorder likely drug
related, occurring at least 1 year after surgery, and one case of
hypomania that required hospital admission.
DISCUSSION
We report a long-term follow-up evaluation of the effect of
high-frequency STN DBS in patients with advanced PD, who
were operated on using a MRI-guided and MRI-veriﬁed
approach without MER. Beneﬁcial antiparkinsonian effects of
DBS on rigidity and tremor in the off-medication state persisted
after a follow-up period of 5 and 8 years. Improvements on dys-
kinesias and motor ﬂuctuations also persisted in the long term.
Motor scores
In our series, the motor scores in the ‘off-medication’ state
assessed by UPDRS-III were signiﬁcantly reduced by stimulation,
leading to an amelioration of the frequency and severity of ‘off ’
periods that remained signiﬁcantly improved in the long term.
Comparison of the UPDRS-III scores in the ‘off ’ medication
state obtained at baseline with the one at 5 and 8 years in the
‘off ’ medication and on stimulation condition revealed sustained
improvement, as has been previously reported.10 22 23 On the
other hand, UPDRS-III on medication signiﬁcantly deteriorated
at 5 and 8 years, mostly driven by axial symptoms and bradyki-
nesia subscores.9 23 This outcome was paralleled by deterior-
ation in the ability to perform daily living activities measured by
UPDRS-II ‘on medication’. As previously reported, the deterior-
ation in axial symptoms, for example, speech and postural
instability, is characteristic of the natural history of PD, likely
due to non-dopaminergic deﬁcits.9
Reduction of dopaminergic therapy responsiveness, a well-
recognised feature of advanced PD, combined with extension of
the PD pathological process beyond the nigro-striatal dopamin-
ergic system, could be partially responsible for this decline in the
long-term response to DBS during the on-medication condi-
tion.24 25 Whether the longer-term deterioration of gait and
balance merely reﬂects disease progression or is partially caused
by chronic high-frequency STN DBS merits further investigation.
Our series demonstrated a positive correlation between
younger age at PD onset and better long-term motor outcome
after STN DBS. However, shorter disease duration or younger
age at surgery did not seem to favourably impact the long-term
motor response to DBS, although a trend was noted for
younger age. It has been shown that younger age at onset is gen-
erally associated with a slower disease progression, likely in
keeping with higher prevalence of some genetic forms of PD.26
As previously reported, delayed deterioration in speech can
occur following STN DBS.9 18 Indeed, a decline in speech intel-
ligibility was observed in this cohort, both during off-
medication and on-medication conditions. Interestingly, this
deterioration was more pronounced during the on-medication
condition in comparison to the off-medication condition.
Cognitive scores
The proportion of patients with severe cognitive decline in our
series was 17.1% at 5 years and was remarkably similar (16.7%)
at 8 years. These rates are relatively lower in comparison to
what has been previously reported (43% in a cohort of patients
followed up >7 years after bilateral STN DBS).22 However, the
cohort of patients described by these authors had higher age at
surgery (61.5±5.7 vs 52.8±10.1 in our 8-year group) and
longer disease duration at STN DBS implantation (22.8±2.3 vs
12.3±4 in our group). Nevertheless, a multicentre study that
followed 35 STN DBS patients (mean disease duration at
surgery 13.5 years, and mean age at surgery 59.6) for 5–6 years
reported cognitive decline in 22.8%, a ﬁgure that is closer to
that found in our series.23
Quality of life
A number of studies have reported on health-related quality of
life after STN DBS showing favourable outcomes over short-
term follow-up.27–30 To our knowledge, this series is the ﬁrst to
report long-term follow-up of quality of life in patients with PD
treated with STN DBS.
In keeping with previously published data, health-related
quality of life measured by PDQ-39 was signiﬁcantly improved
after STN-DBS in 1 year in our series. Total PDQ-39 scores
have returned to baseline levels, although remained slightly
better, at 5- and 8-year follow-up. Subdomains such as mobility,
ADL, stigma, support and bodily discomfort were the ones
showing a more sustained improvement over time. Conversely,
emotional well-being, cognition and communication subdo-
mains declined at 5 and 8 years.
The development of non-levodopa-responsive features could
be, at least partially, responsible for the decline in quality of life
from 1 year to 5- and 8-year follow-up in our series.
Anxiety and depression
It has been suggested that STN DBS may have an antidepressant
effect in PD over time.31 Although higher levels of transient
depressive disorders have been reported after the intervention,32
especially in the short term, it is mostly reported that depression
and anxiety tend to improve in the ﬁrst years after STN DBS.33
Nonetheless, depression and anxiety scores tend to reach base-
line levels in studies reporting longer follow-up results.
Accordingly, in our cohort, there was no signiﬁcant change in
depression or anxiety at long-term follow-up relative to
baseline.
MRI-guided and MRI-veriﬁed DBS
The low morbidity of the MRI-guided and MRI-veriﬁed
approach to surgery employed in this series demonstrates a high
standard of safety while maintaining therapeutic efﬁcacy.34 We
are not aware of any other report on the long-term follow-up of
patients with PD who had surgery with MRI-guided and
MRI-veriﬁed STN DBS without use of MER. The optimal
target point within the visualised STN is still disputed.35
Initially, we targeted the centre of the visualised STN as
described by Bejjani et al.36 Ongoing audit of lead location and
associated clinical results eventually resulted in the intended
target point being located 2 or 3 mm posterolateral to that
described by Bejjani. Thus, we currently target the most super-
ior, posterior and lateral portion of the nucleus, thought to be
the sensorimotor STN.20 21 These areas are equivalent to those
labelled 1 and 2. Our data suggest that there is a signiﬁcant cor-
relation between lead location associated with these regions of
the STN and superior improvement in motor outcomes. Other
authors have reported that lead location in relation to the STN
on postoperative imaging can predict clinical outcome.37 38 Our
ﬁndings extend this concept to long-term clinical outcome.
The risk of symptomatic haemorrhage inevitably rises with
increasing numbers of micro-electrode or macro-electrode brain
penetrations. MRI-guided and MRI-veriﬁed surgery has been
associated with a signiﬁcantly reduced risk of haemorrhagic
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complications in functional neurosurgery.34 Accordingly, none
of the patients in this series had visible haemorrhage on their
postoperative imaging, conﬁrming that a meticulous approach
to MRI-guided and MRI-veriﬁed DBS is safe and accurate, with
clinical outcomes comparable to other techniques, yet with a
reduced risk associated with surgery.
Despite the lack of double-blind assessments and the relatively
small sample size, our results suggest that motor improvements
following STN DBS can be sustained beyond 8 years.
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